The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial.
Study participants will be randomly assigned to receive either tamoxifen or placebo for one
year. Participants will subsequently be followed for one year off of medication. The primary
objective is to evaluate the effectiveness of tamoxifen in reducing breast density by
mammogram.